Alliancebernstein L.P. Acquires 84,255 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Alliancebernstein L.P. raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 3.8% in the 4th quarter, HoldingsChannel reports. The firm owned 2,286,994 shares of the company’s stock after purchasing an additional 84,255 shares during the quarter. Alliancebernstein L.P.’s holdings in Viridian Therapeutics were worth $43,842,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of VRDN. Charles Schwab Investment Management Inc. raised its holdings in shares of Viridian Therapeutics by 6.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 516,213 shares of the company’s stock valued at $11,744,000 after buying an additional 32,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Viridian Therapeutics by 17.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock valued at $318,000 after acquiring an additional 2,036 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Viridian Therapeutics by 29.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 89,496 shares of the company’s stock worth $2,036,000 after acquiring an additional 20,166 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Viridian Therapeutics during the third quarter valued at approximately $788,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Viridian Therapeutics during the third quarter valued at approximately $660,000.

Viridian Therapeutics Stock Down 5.2 %

Shares of NASDAQ:VRDN opened at $11.99 on Friday. The company has a 50 day moving average price of $16.18 and a two-hundred day moving average price of $19.42. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market capitalization of $977.01 million, a PE ratio of -2.78 and a beta of 0.81. Viridian Therapeutics, Inc. has a 52 week low of $11.31 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Royal Bank of Canada upped their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.